TRIANGLE THERAPEUTICS INC.

Sherman Oaks, CA · Biotech

TRE-515, a small molecule drug that inhibits deoxycytidine kinase (dCK) to selectively target cancer cells

trethera.com →
Grants
$1.3M
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleotide Salvage Pathway to Treat Underserved Tumor Types$1,349,805
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3100TUNITAS THERAPEUTICS, INC.——
3101KL50 THERAPEUTICS, LLC——
3102Medical Guidance Systems LLC——
3103TRIANGLE THERAPEUTICS INC.——
3104Thimble Therapeutics Inc——
3105EPIVAX, INC.——
3106Cortendo——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.